NAME ADAM JACOBS DOES

Brand	Owner	Address	Description
ADAM JACOBS	PICADILLY FASHIONS INC.	4050 CHESSWOOD DRIVE TORONTO, ONTARIO M3J2B9 Canada	The name ADAM JACOBS does not identify a living individual.;Clothing, namely, pants, skirts, dresses, shorts, shirts, suits, blouses, tank tops, sweaters, jackets, coats, jeans, t-shirts, vests, sports jackets, scarves, shawls, hats, socks, gloves, pajamas, night wear, robes and hosiery; women's clothing, namely, pants, skirts, dresses, shorts, shirts, suits, blouses, tank tops, sweaters, jackets, coats, jeans, t-shirts, vests, sports jackets, lingerie, bras, pajamas, night wear, robes, hosiery and leggings; women's activewear clothing, namely, bras, pants, tops, shorts and jackets; men's clothing, namely, pants, skirts, dresses, shorts, shirts, suits, blouses, tank tops, sweaters, jackets, coats, jeans, t-shirts, vests, sports jackets, scarves, hats, socks, gloves, pajamas and robes; men's activewear clothing, namely, pants, tops, shorts and jackets; jewelery, women's hair ornaments, handbags, wallets, travel bags, water bottles;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.